Showing 2161-2170 of 3223 results for "".
- Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DMEhttps://modernod.com/news/alimera-announces-iluvien-regulatory-approval-in-australia-for-the-treatment-of-dme/2479552/Alimera Sciences announced that the Australian Therapeutic Goods Administration (TGA), the division of the Australian Department of Health that oversees the availability of medical products, has approved Iluvien (190 micrograms intravitreal implant in applicator) for the treatment of diabetic mac
- US Outlines Plans to Allow Importation of Certain Prescription Drugs From Canada, Other Countrieshttps://modernod.com/news/us-outlines-plans-to-allow-importation-of-certain-prescription-drugs-from-canada-other-countries/2479556/The US Department of Health and Human Services (HHS) on Wednesday outlined details of two potential pathways that will allow the importation of certain prescription medicines originally intended for foreign markets. The announcement comes the day after HHS Secretary Alex Azar confirmed that Presi
- Altris AI Algorithm for Detection of Retinal Conditions on OCT Scans Receives European CE Mark Approvalhttps://modernod.com/news/altris-ai-algorithm-for-detection-of-retinal-conditions-on-oct-scans-receives-european-ce-mark-approval/2479561/Altris AI announced that it has received the CE Mark approval for its Standard Functionality for retinal conditions detection on Optical Coherence Tomography (OCT) scans. Altris AI Standard Functionality is ready for preliminary screening of retinal diseases in clinical practice. Altris AI detect
- Doctor Alexa Will See You Now: Is Amazon Primed To Come To Your Rescue?https://modernod.com/news/doctor-alexa-will-see-you-now-is-amazon-primed-to-come-to-your-rescue/2476782/Now that it’s upending the way you play music, cook, shop, hear the news and check the weather, the friendly voice emanating from your Amazon Alexa-enabled smart speaker is poised to wriggle its way into all things health care. Amazon has big ambitions for its devices, according to a
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- Alcon Showcases New Vitrectomy Probe and Next Generation Ngenuity 3D Visualization System at ASRShttps://modernod.com/news/alcon-showcases-new-vitrectomy-probe-and-nextgeneration-ngenuity-3d-visualization-system-at-asrs/2476772/Alcon is introducing the Hypervit Dual Blade Vitrectomy Probe, the newest addition to the Constellation Vision System, at the American Society of Retina Specialists (ASRS) 2019 annual meeting taking place July 26-30 in Chicago. The company is also featuring its next generation Ngenuity 3D Visuali
- Allegro Ophthalmics to Present Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at ASRShttps://modernod.com/news/allegro-ophthalmics-to-present-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-asrs/2476765/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD) will be presented during the Americ
- Alcon Launches New Website to Educate Patients on LASIK and Contoura Visionhttps://modernod.com/news/alcon-launches-new-website-to-educate-patients-on-lasik-and-contoura-vision/2476758/Alcon has launched a new website, yourlasiksolution.com, to help educate patients about LASIK and surgery options, including its WaveLight LASIK technology with Contoura Vision. Alcon gathered input from real-world LASIK patients about the type of information that was critical to make an informed
- Altaire Pharmaceuticals Expands Voluntary Recall Of Multiple OTC Ophthalmic Productshttps://modernod.com/news/altaire-pharmaceuticals-expands-voluntary-recall-of-multiple-otc-ophthalmic-products/2476747/Altaire Pharmaceuticals announced that it is voluntarily recalling the over-the-counter (OTC) drug products and lots, within expiry, sold by Accutome, Focus Laboratories, Grandall Distributing Co., and Prestige Brands. As a precautionary measure, Altaire is voluntarily initiating the recall due t
- FDA Accepts Allergan’s NDA for Bimatoprost SR in Patients With Glaucomahttps://modernod.com/news/fda-accepts-allergans-nda-for-bimatoprost-sustained-release-in-patients-with-open-angle-glaucoma-or-ocular-hypertension/2476739/Allergan announced that the FDA has accepted the company’s new drug application (NDA) for Bimatoprost Sustained-Release (SR) biodegradable implant for the reduction of IOP in patients with primary open-angle glaucoma or ocular hypertension. The FDA is expected to take action on the NDA by t